An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Mavoglurant (Primary)
- Indications Anxiety disorders
- Focus Pharmacokinetics
- 01 Oct 2011 New trial record